PHAT

Healthcare Biotechnology

Phathom Pharmaceuticals, Inc.

$6.92

-0.38 -5.21% today

Price History

Not enough data

Key Stats

Market Cap

559.83M

Avg Volume

1.38M

EPS

-$1.26

52W High

$18.31

52W Low

$6.82

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

6.43

P/B Ratio

-1.61

P/S Ratio

2.34

EV/EBITDA

-23.16

EV/Revenue

3.88

Margins

Gross Margin 82.9%

Operating Margin (5.3%)

Net Margin (41.3%)

EBITDA Margin (16.7%)

Growth & Returns

Revenue Growth (YoY)

88.0%

Return on Assets

(8.8%)

Liquidity & Leverage

Current Ratio

1.92

Quick Ratio

1.82

Total Cash

182.48M

Total Debt

552.02M

About

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.